Precision medicines have the ability to transform healthcare and treat a myriad of unmet medical needs. The Caribou technology platform has the ability to generate transformative medicines in multiple different market segments.
Our current therapeutic areas of exploration include anti-microbials, animal health, and therapeutic bioproduction.
In 2014, Caribou co-founded Intellia Therapeutics to develop curative medicines utilizing the Caribou CRISPR-Cas9 platform.
Intellia is developing human gene and cell therapies for both ex vivo and in vivo applications using CRISPR-Cas9 gene editing technology. Near-term ex vivo applications include the treatment of blood disorders and cancer. In January 2015, Intellia announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR-Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoetic stem cells (HSCs).
Substantial research into the microbiome has shed light on the sophisticated interplay between humans and the microbes that live in and on us. The Caribou technology platform holds the potential for developing targeted anti-bacterial therapies to modulate or eliminate specific strains of bacteria within complex communities containing many different bacterial strains.
The Caribou technology platform holds significant promise for unlocking new therapies to treat household pets. The CRISPR-Cas technology can be used to screen for druggable targets and to develop gene and cell therapies for unmet medical needs.
The Caribou technology platform also has the potential to offer new treatments for unmet medical needs within livestock and address the growing global demand for reliable food sources and improved food safety.
Many life-saving products, such as recombinant therapeutic proteins, vaccines, and gene therapy vectors, are produced from large-scale cell culture systems. The Caribou technology platform and our scientific capabilities can improve these cell systems to yield larger quantities and higher qualities of therapeutic biomaterials.
In Depth - Therapeutics
Therapeutic applications of CRISPR-Cas gene editing are being advanced with the goals of finding cures and treatments for a range of serious diseases, developing needed medicines for both household pets and production animals, and improving cell culture systems for bioproduction.